Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A method of treating or preventing a pathological condition of the uterus in a female individual, the method comprising administering to the individual at least one agent that prevents $PGF_{2\alpha}$ having its effect on the FP receptor.

2. (Original) A method according to Claim 1 wherein the pathological condition of the uterus is associated with abnormal growth of cells of the myometrium or endometrium.

3. (Currently Amended) A method according to Claim 1 ~~or 2~~ wherein the pathological condition of the uterus is uterine carcinoma or an endometrial or myometrial pathological condition.

4. (Original) A method according to Claim 3 wherein the endometrial pathological condition is endometriosis.

5. (Original) A method according to Claim 3 wherein the myometrial pathological condition is fibroids.

6. (Currently Amended) A method according to ~~any one of Claims 1 to 5~~ Claim 1 wherein the agent that prevents $PGF_{2\alpha}$ having its effect on the FP receptor prevents or reduces the binding of $PGF_{2\alpha}$ to the FP receptor.

7. (Currently Amended) A method according to ~~any one of Claims 1 to 6~~ Claim 1 wherein the agent that prevents $PGF_{2\alpha}$ having its effect on the FP receptor affects the interaction between $PGF_{2\alpha}$ and the FP receptor, or the interaction between the FP receptor and the associated $G_{\alpha q}$ protein, thus inhibiting or disrupting a $PGF_{2\alpha}$,-FP mediated signal transduction pathway.

8. (Currently Amended) A method according to ~~any one of Claims 1 to 7~~ Claim 1 wherein the agent is an antagonist of the FP receptor.

9. (Original) A method according to Claim 8 wherein the FP receptor antagonist to any one or more of $PGF_{2\alpha}$ dimethyl amide; $PGF_{2\alpha}$, dimethyl amine; AL-8810 ((5Z,13E)-(9S,11S,15R)-9,15-dihydroxy-11-fluoro-15-(2-indanyl)-16,17,18,19,20-pentanor-

5,13-prostadienoic acid); AL-3138 (11-deoxy-16-fluoro $PGF_{2\alpha}$); phloretin; glibenclamide; ridogrel; PHG113, PCP-1 (rvkfksqqhrqgrshhlem); PCP-2 (rkavlknlyklasqccgvhvislhiwelssiknslkvaaisespvaeksast); PCP-3 (clseeakearrindeierqlrrdkrdarre-NH_2); PCP-4 (kdtilqlnlkeynlv-NH_2); PCP-8 (ilghrdyk); PCP-10 (wedrfyll); PCP-13 (ILGHRDYK); PCP-14 (YQDRFYLL); (ILAHRDYK); PCP-13.7 (ILAHRDYK); PCP-13.8 (ILaHRDYK); PCP-13.11 (ILGFRDYK); PCP-13.13 (ILGHKDYK); PCP-13.14 (ILGHRNYK); PCP-13.18 (ILGHQDYK); PCP-13.20 (ILGHRDY-amide) ; PCP-13.21 (ILGHRDYK-amide); PCP-13.22 (ILGWRDYK); PCP-13.24 (ILGXRDYK); and PCP-15 (SNVLCSIF).

10. (Currently Amended) A method according to ~~any one of Claims 1 to 7~~ Claim 1 wherein the agent is an antagonist of $PGF_{2\alpha}$.

11. (Currently Amended) A method according to Claim 10 wherein the $PGF_{2\alpha}$ antagonist is an anti-$PGF_{2\alpha}$ antibody.

12. (Currently Amended) A method according to any of ~~Claims 1 to 11 wherein~~ Claim 1 further comprising administering to the individual an inhibitor of PGES and/or an antagonist of EP2 or EP4 ~~is also administered to the individual~~.

13. (Original) A method according to Claim 12 wherein the antagonist of EP2 or EP4 is one or more of AH6809, an omega-substituted prostaglandin E derivative ~~described in WO 00/15608 (Ono Pharm Co Ltd)~~, AH23848B, AH22921X, IFTSYLECL, IFASYECL, IFTSAECL, IFTSYEAL, IFASYECL, IFTSTDCL, TSYEAL (with 4-biphenylalanine), TSYEAL (with homophenylalanine), a 5-thia-prostaglandin E derivative ~~described in WO 00/03980 (Ono Pharm Co Ltd)~~, 5-butyl-2,4-dihydro-4-[[2'-[N-(3-chloro-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one potassium salt, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-methyl-3-furoyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(3-methyl-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, and 5-butyl-2,4-dihydro-4-[[2'-[N-[2-(methypyrrole)carbonyl]sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one.

14. (Original) Use of at least one agent that prevents $PGF_{2\alpha}$ having its effect on the FP receptor, in the manufacture of a medicament for treating or preventing a pathological condition of the uterus in a female individual.

15. (Original) Use according to Claim 14, wherein the individual is administered an inhibitor of PGES and/or an antagonist of EP2 or EP4.

16. (Original) Use of an inhibitor of PGES and/or an antagonist of EP2 or EP4 in the manufacture of a medicament for treating or preventing a pathological condition of the uterus in a female individual, wherein the individual is administered at least one agent that prevents $PGF_{2\alpha}$ having its effect on the FP receptor.

17. (Original) Use of a combination of at least one agent that prevents $PGF_{2\alpha}$ having its effect on the FP receptor, and an inhibitor of PGES and/or an antagonist of EP2 or EP4, in the manufacture of a medicament for treating or preventing a pathological condition of the uterus in a female individual.

18. (Currently Amended) Use according to ~~any one of Claims 14-17~~ Claim 14 wherein the pathological condition of the uterus is uterine carcinoma or an endometrial or myometrial pathological condition.

19. (Original) A pharmaceutical composition comprising at least one agent that prevents $PGF_{2\alpha}$ having its effect on the FP receptor for treating or preventing a pathological condition of the uterus in a female individual.

20. (Currently Amended) A pharmaceutical composition according to Claim 19 further ~~and also~~ comprising an inhibitor of PGES and/or an antagonist of EP2 or EP4.

21. (Currently Amended) A pharmaceutical composition according to Claim 19 ~~or 20~~ wherein the pathological condition of the uterus is uterine carcinoma or an endometrial or myometrial pathological condition.

22. (Original) A vaginal ring or a tampon or an intrauterine device comprising at least one agent that prevents $PGF_{2\alpha}$ having its effect on the FP receptor.

23. (Original) A vaginal ring or a tampon or an intrauterine device according to Claim 22 wherein the agent comprises an antagonist of the FP receptor.

24. (Original) A vaginal ring or a tampon or an intrauterine device according to Claim 23 wherein the FP receptor antagonist comprises any one or more of $PGF_{2\alpha}$ dimethyl amide; $PGF_{2\alpha}$ dimethyl amine; AL-8810 ((5Z,13E)-(9S,11S,15R)-9,15-dihydroxy-11-fluoro-15-(2-indanyl)-16,17,18,19,20-pentanor-5,13-prostadienoic acid); AL-3138 (11-deoxy-16-fluoro $PGF_{2\alpha}$); phloretin; glibenclamide; ridogrel; PHG113; PCP-1 (rvkfksqqhrqgrshhlem); PCP-2 (rkavlknlyklasqccgvhvislhiwelssiknslkvaaisespvaeksast); PCP-3 (clseeakearrindeierq]rrdkrdarre-NH_2); PCP-4 (kdtilqlnlkeynlv-NH_2); PCP-8 (ilghrdyk); PCP-10 (wedrfyll); PCP-13 (ILGHRDYK); PCP-14 (YQDRFYLL); (ILAHRDYK); PCP-13.7 (ILAHRDYK); PCP-13.8 (ILaHRDYK); PCP-13.11 (lLGFRDYK); PCP-13.13 (ILGHKDYK); PCP-13.14 (IT,GHRNYK); PCP-13.18 (ILGHQDYK); PCP-13.20 (ILGHRDY-amide); PCP-13.21 (ILGHRDYK-amide); PCP-13.22 (ILGWRDYK); PCP-13.24 (ILGXRDYK); and PCP-15 (SNVLCSIF).

25. (Original) A vaginal ring or a tampon or an intrauterine device according to Claim 22 wherein the agent comprises an antagonist of $PGF_{2\alpha}$.

26. (Original) A vaginal ring or a tampon or an intrauterine device according to Claim 25 wherein the $PGF_{2\alpha}$ antagonist comprises anti-$PGF_{2\alpha}$ antibodies.

27. (Currently Amended) A vaginal ring or a tampon or an intrauterine device according to ~~any one of Claims 22 to 26~~ Claim 22 further comprising an inhibitor of PGES and/or an antagonist of EP2 or EP4.

28. (Currently Amended) A vaginal ring or a tampon or an intrauterine device according to Claim 27 wherein the antagonist of EP2 or EP4 is one or more of AH6809, an omega-substituted prostaglandin E derivative ~~described in WO 00/15608 (Ono Pharm Co Ltd)~~, AH23848B, AH22921X, IFTSYLECL, IFASYECL, IFTSAECL, IFTSYEAL, ILASYECL, IFTSTDCL, TSYEAL (with 4-biphenylalanine), TSYEAL (withomophenylalanine), a 5-thia-prostaglandin E derivative ~~described in WO 00/03980 (Ono Pharm Co Ltd)~~, 5-butyl-2,4-dihydro-4-[[2'-[N-(3-chloro-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one potassium salt, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-methyl-3-furoyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(3-methyl-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-

(2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, and 5-butyl-2,4-dihydro-4-[[2'-[N-[2-(methypyrrole)carbonyl]sulfamoyl biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3- one.

29. (Original) A composition comprising at least one agent that prevents $PGF_{2\alpha}$ having its effect on the FP receptor, and an inhibitor of PGES and/or an antagonist of EP2 or EP4.

30. (Original) A pharmaceutical composition comprising at least one agent that prevents $PGF_{2\alpha}$ having its effect on the FP receptor, and an inhibitor of PGES and/or an antagonist of EP2 or EP4, and a pharmaceutically acceptable carrier.

31. (Original) A composition according to Claim 29 for use in medicine.